m-tolyl 5- chloro- 2- (ethylsulfonyl)pyrimidine- 4- carboxylate
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Chen, Yi:
1 article
(06/2022)
|
| 2. | Gao, Shanshan:
1 article
(06/2022)
|
| 3. | Gong, Gaoquan:
1 article
(06/2022)
|
| 4. | Lei, Ming:
1 article
(06/2022)
|
| 5. | Lei, Yangyang:
1 article
(06/2022)
|
| 6. | Li, Changyu:
1 article
(06/2022)
|
| 7. | Li, Guoping:
1 article
(06/2022)
|
| 8. | Li, Jianke:
1 article
(06/2022)
|
| 9. | Wang, Chenggang:
1 article
(06/2022)
|
| 10. | Wang, Xiaolin:
1 article
(06/2022)
|
Related Diseases
| 1. | Pancreatic Neoplasms (Pancreatic Cancer)
|
| 2. | Cysts
10/01/2017
- " Levels of cAMP, cell proliferation, and cyst growth in vitro were decreased by ∼30% in cystic cholangiocytes after treatment with SBI-115 alone and by ∼50% when SBI-115 was combined with pasireotide. " 10/01/2017
- " In vitro, we assessed cholangiocyte proliferation, cAMP levels, and cyst growth in response to (1) TGR5 agonists (taurolithocholic acid, oleanolic acid [OA], and two synthetic compounds), (2) a novel TGR5 antagonist (m-tolyl 5-chloro-2-[ethylsulfonyl] pyrimidine-4-carboxylate [SBI-115]), and (3) a combination of SBI-115 and pasireotide, a somatostatin receptor analogue. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures